189333-03-7 Usage
Description
TERT-BUTYL 2,9-DIAZASPIRO[5.5]UNDECANE-2-CARBOXYLATE is a spirooxazolidine derivative, a chemical compound characterized by its molecular formula C16H31N3O2. It is known for its diverse range of biological and pharmaceutical applications and is commonly utilized as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. This colorless liquid with a distinctive odor is handled and stored following standard chemical safety protocols.
Uses
Used in Pharmaceutical Industry:
TERT-BUTYL 2,9-DIAZASPIRO[5.5]UNDECANE-2-CARBOXYLATE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, TERT-BUTYL 2,9-DIAZASPIRO[5.5]UNDECANE-2-CARBOXYLATE is employed as an intermediate in the production of agrochemicals, aiding in the creation of compounds that can enhance crop protection and yield.
Used in Organic Synthesis:
TERT-BUTYL 2,9-DIAZASPIRO[5.5]UNDECANE-2-CARBOXYLATE is utilized as a versatile building block in organic synthesis, enabling the formation of a wide array of organic compounds for various applications across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 189333-03-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,9,3,3 and 3 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 189333-03:
(8*1)+(7*8)+(6*9)+(5*3)+(4*3)+(3*3)+(2*0)+(1*3)=157
157 % 10 = 7
So 189333-03-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H26N2O2/c1-13(2,3)18-12(17)16-10-4-5-14(11-16)6-8-15-9-7-14/h15H,4-11H2,1-3H3
189333-03-7Relevant articles and documents
Spirocyclic derivatives
-
Page/Page column 181; 182, (2016/04/09)
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.